The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate...
Saved in:
Published in | Quantitative imaging in medicine and surgery Vol. 8; no. 7; pp. 709 - 718 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
AME Publishing Company
01.08.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment. |
---|---|
AbstractList | Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8
th
edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7
th
edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7
th
edition is further subcategorized into M1b and M1c in the 8
th
edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8
th
edition, as well as discussion on the implications on treatment. Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment.Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing management option in lung cancer patients. Guidelines are constantly being reviewed as more data becomes available to provide the most accurate prognostic markers, hence aiding in the clinical detection and staging of lung cancer. Since its introduction in the 1970s, the TNM staging has undergone significant revisions with the latest, 8th edition, being effective internationally from 2018. This edition re-categorizes the tumour size and other non-quantitative tumour descriptors (T), and further subclassifies extra-thoracic metastases (M). The clinical nodal (N) classifier is unchanged as the earlier version correlates well with prognosis. The downstream effects on staging to accommodate for the new T and M classifications are highlighted. The survival is inversely proportional to every centimeter increase in tumour size up till 7 cm, where the same prognosis as a T4 disease is reached. Hence, some of the T-classifiers based on size of the tumour is upstaged to reflect that. Invasion of the diaphragm is considered T4 instead of T3. On the other hand, involvement of the main bronchus regardless of tumour distance to carina as well as atelectasis is down-staged from a T3 to a T2 disease. Since the 7th edition, new entities of lung tumour known as adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced. The T-defining features are also described in this manuscript. Extrathoracic metastases that were classified as M1b in the 7th edition is further subcategorized into M1b and M1c in the 8th edition, to better define oligometastasis which has a better prognosis, and may benefit from more aggressive local therapy. This overview aims to provide radiologists with a description of the changes in the latest edition including staging of subsolid and multiple nodules, outline potential limitations of this 8th edition, as well as discussion on the implications on treatment. |
Author | Mirsadraee, Saeed Nicholson, Andrew G. Ridge, Carole A. Lim, Wanyin |
Author_xml | – sequence: 1 givenname: Wanyin surname: Lim fullname: Lim, Wanyin – sequence: 2 givenname: Carole A. surname: Ridge fullname: Ridge, Carole A. – sequence: 3 givenname: Andrew G. surname: Nicholson fullname: Nicholson, Andrew G. – sequence: 4 givenname: Saeed surname: Mirsadraee fullname: Mirsadraee, Saeed |
BookMark | eNp1kctPAyEQxonR-L575OildRjqPjyYGOMr8XHpnQDLthiWrTtU0_9eqvWgiWQSBub7foF8B2w79tExdiJgjAJkefbmOxojiGoMuXCL7SOiHE0kFNs_Pda4x46JXiGvshKlgF22JwHFGrHPaDp3vEpzHpZxxq2O1g18-vzEbdBEvvVWJ99HrmOTr3zM58Ap6ZnPclpRct0FH9y7dx-8b3nKNDvXcebot8V3i7Bh0RHbaXUgd7zZD9n09mZ6fT96fLl7uL56HFlZ1GlktWhlWQAa20hrJtgYiQDFxOjaSIOtlqbM80ktGpS1BWeLptJN7UxlhZaH7PIbu1iazjXWxTTooBaD7_SwUr326vck-rma9e-qEFieI2TA6QYw9G9LR0l1nqwLQUfXL0mtUyhKhHORpcW31A490eBaZX36-m0m-6AEfKlLtc5MrTNTkAuzEf4Yf973r-UTcImdzA |
CitedBy_id | crossref_primary_10_1053_j_semnuclmed_2022_04_011 crossref_primary_10_1016_j_jtho_2023_08_011 crossref_primary_10_1016_j_thorsurg_2021_07_010 crossref_primary_10_1016_j_rmcr_2020_101074 crossref_primary_10_1186_s43168_022_00133_x crossref_primary_10_1002_cam4_4560 crossref_primary_10_1186_s13014_021_01904_4 crossref_primary_10_1186_s12885_022_10333_9 crossref_primary_10_3390_cancers14235994 crossref_primary_10_1002_jcla_24412 crossref_primary_10_1016_j_cllc_2022_02_002 crossref_primary_10_1042_BSR20203097 crossref_primary_10_12729_jbtr_2024_25_4_221 crossref_primary_10_3390_curroncol28030157 crossref_primary_10_1245_s10434_024_15762_3 crossref_primary_10_1080_02656736_2021_1902000 crossref_primary_10_3390_cancers16030506 crossref_primary_10_1136_bmjopen_2021_057638 crossref_primary_10_1007_s00117_022_01102_7 crossref_primary_10_2217_fon_2022_1216 crossref_primary_10_3892_ol_2022_13558 crossref_primary_10_1097_MNM_0000000000001367 crossref_primary_10_2217_epi_2020_0399 crossref_primary_10_3389_fmed_2021_680679 crossref_primary_10_1016_j_jtcvs_2024_10_053 crossref_primary_10_3390_medicina57040393 crossref_primary_10_1089_jayao_2021_0069 crossref_primary_10_1016_j_jvir_2021_05_006 crossref_primary_10_1183_16000617_0174_2022 crossref_primary_10_1016_j_heliyon_2023_e16865 crossref_primary_10_1515_iss_2020_0010 crossref_primary_10_1007_s11306_022_01918_3 crossref_primary_10_1055_a_1714_1941 crossref_primary_10_2967_jnmt_124_267843 crossref_primary_10_1016_j_remnie_2020_09_012 crossref_primary_10_1186_s12967_020_02606_3 crossref_primary_10_1177_15330338221133222 crossref_primary_10_1016_j_jmig_2021_07_023 crossref_primary_10_1016_j_clinimag_2020_11_048 crossref_primary_10_1080_02656736_2021_1914353 crossref_primary_10_3389_fonc_2023_1117348 crossref_primary_10_1080_02656736_2021_1885755 crossref_primary_10_1097_CCO_0000000000001005 crossref_primary_10_1155_2021_1436088 crossref_primary_10_3389_fonc_2021_643261 crossref_primary_10_1007_s00330_021_07865_2 crossref_primary_10_1016_j_jtho_2023_09_277 crossref_primary_10_1093_jjco_hyac204 crossref_primary_10_1093_icvts_ivab209 crossref_primary_10_18794_aams_163055 crossref_primary_10_3390_biomedinformatics4040129 crossref_primary_10_1007_s12149_021_01694_5 crossref_primary_10_3892_mmr_2021_12227 crossref_primary_10_1186_s12885_022_09908_3 crossref_primary_10_4103_ijnm_IJNM_170_20 crossref_primary_10_1186_s12885_024_13268_5 crossref_primary_10_21294_1814_4861_2020_19_4_105_111 crossref_primary_10_1002_cam4_4990 crossref_primary_10_1055_a_1517_8525 crossref_primary_10_1111_1759_7714_13129 crossref_primary_10_17116_hirurgia202212120 crossref_primary_10_1016_j_resmer_2022_100887 crossref_primary_10_1177_15330338211039676 crossref_primary_10_1016_j_lungcan_2020_10_004 crossref_primary_10_1016_j_remn_2020_06_025 crossref_primary_10_4103_aca_aca_132_22 crossref_primary_10_2217_imt_2019_0105 crossref_primary_10_3892_ol_2024_14637 crossref_primary_10_7759_cureus_80200 crossref_primary_10_3322_caac_21785 crossref_primary_10_1155_2022_6619331 crossref_primary_10_3892_ol_2021_13155 crossref_primary_10_1016_j_intimp_2022_109391 crossref_primary_10_7717_peerj_16923 crossref_primary_10_1186_s13019_023_02380_5 crossref_primary_10_3390_ijms22168885 crossref_primary_10_1136_bmjopen_2021_052556 crossref_primary_10_1186_s11658_024_00636_z crossref_primary_10_1155_2022_5698582 crossref_primary_10_1016_j_lungcan_2024_107471 crossref_primary_10_1097_RLU_0000000000003903 crossref_primary_10_3390_jcm13154570 crossref_primary_10_1016_j_clon_2021_07_008 crossref_primary_10_2217_bmm_2019_0583 crossref_primary_10_5582_ddt_2019_01032 crossref_primary_10_3389_fonc_2021_696732 crossref_primary_10_1002_ima_22858 crossref_primary_10_1016_j_ijscr_2020_03_021 crossref_primary_10_2147_OTT_S243221 crossref_primary_10_18632_aging_205183 crossref_primary_10_3390_jcm13051450 crossref_primary_10_1111_1759_7714_13213 crossref_primary_10_2147_CMAR_S254139 crossref_primary_10_3389_fonc_2022_881015 crossref_primary_10_1111_1759_7714_15253 crossref_primary_10_21641_los_2020_17_4_190 crossref_primary_10_1080_02656736_2021_1976852 crossref_primary_10_1200_GO_21_00100 crossref_primary_10_1007_s12149_022_01795_9 crossref_primary_10_3904_kjim_2021_488 crossref_primary_10_1016_j_chest_2023_11_042 crossref_primary_10_2147_JIR_S402108 crossref_primary_10_3389_fonc_2022_942964 crossref_primary_10_1016_j_lungcan_2024_107868 crossref_primary_10_1016_j_mpdhp_2022_08_004 crossref_primary_10_1093_hropen_hoab025 crossref_primary_10_1097_MD_0000000000028617 crossref_primary_10_1097_MD_0000000000025748 crossref_primary_10_1111_1759_7714_13861 crossref_primary_10_1038_s41419_024_07129_z crossref_primary_10_1177_10760296231159121 crossref_primary_10_1186_s13019_024_02922_5 crossref_primary_10_3389_fcell_2021_797984 crossref_primary_10_2174_0118743064318977240531100045 crossref_primary_10_1016_j_heliyon_2024_e36881 crossref_primary_10_2214_AJR_20_23025 crossref_primary_10_1002_cam4_3055 crossref_primary_10_1016_j_jtocrr_2021_100165 crossref_primary_10_1186_s12911_022_01975_7 crossref_primary_10_3390_cancers16091655 crossref_primary_10_1097_COC_0000000000000828 crossref_primary_10_7759_cureus_17992 crossref_primary_10_1016_j_heliyon_2023_e17969 crossref_primary_10_1111_1759_7714_13711 crossref_primary_10_52054_FVVO_13_3_025 crossref_primary_10_1142_S0192415X22500847 crossref_primary_10_3390_cancers15102855 crossref_primary_10_1016_j_jtcvs_2023_09_048 crossref_primary_10_1097_RLU_0000000000004295 crossref_primary_10_1097_MD_0000000000034184 crossref_primary_10_18632_aging_204112 crossref_primary_10_1016_j_intimp_2023_111147 crossref_primary_10_1007_s11604_022_01366_y crossref_primary_10_1016_j_bbrep_2024_101833 crossref_primary_10_1016_j_ejrad_2021_109718 crossref_primary_10_1016_j_suronc_2020_12_008 crossref_primary_10_1111_1754_9485_13720 crossref_primary_10_1155_2019_2901840 crossref_primary_10_3389_fonc_2022_933278 crossref_primary_10_5306_wjco_v15_i6_755 crossref_primary_10_1007_s13246_021_00988_2 crossref_primary_10_3390_diagnostics11030425 crossref_primary_10_1038_s41598_024_66307_3 crossref_primary_10_1097_COC_0000000000001116 crossref_primary_10_1002_cam4_7024 crossref_primary_10_1016_j_celrep_2021_109905 crossref_primary_10_1245_s10434_020_09151_9 crossref_primary_10_1177_00033197231213197 crossref_primary_10_1186_s12890_021_01817_8 crossref_primary_10_4103_ecdt_ecdt_54_23 crossref_primary_10_1002_ccr3_6859 crossref_primary_10_3233_CBM_182333 crossref_primary_10_18332_pne_161745 |
ContentType | Journal Article |
Copyright | 2018 Quantitative Imaging in Medicine and Surgery. All rights reserved. 2018 Quantitative Imaging in Medicine and Surgery. |
Copyright_xml | – notice: 2018 Quantitative Imaging in Medicine and Surgery. All rights reserved. 2018 Quantitative Imaging in Medicine and Surgery. |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.21037/qims.2018.08.02 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2223-4306 |
EndPage | 718 |
ExternalDocumentID | PMC6127520 10_21037_qims_2018_08_02 |
GroupedDBID | 53G AAKDD AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION DIK HYE OK1 RPM 7X8 5PM |
ID | FETCH-LOGICAL-c369t-ca1f37602bcd3cb42db320064ba9b3b2fa3b7760491d239c0ec6d8ad9eb8c1a3 |
ISSN | 2223-4292 |
IngestDate | Thu Aug 21 14:05:59 EDT 2025 Fri Jul 11 01:08:27 EDT 2025 Tue Jul 01 02:30:29 EDT 2025 Thu Apr 24 23:13:18 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c369t-ca1f37602bcd3cb42db320064ba9b3b2fa3b7760491d239c0ec6d8ad9eb8c1a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://qims.amegroups.com/article/viewFile/20898/20517 |
PMID | 30211037 |
PQID | 2103672051 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6127520 proquest_miscellaneous_2103672051 crossref_citationtrail_10_21037_qims_2018_08_02 crossref_primary_10_21037_qims_2018_08_02 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-8-00 20180801 |
PublicationDateYYYYMMDD | 2018-08-01 |
PublicationDate_xml | – month: 08 year: 2018 text: 2018-8-00 |
PublicationDecade | 2010 |
PublicationTitle | Quantitative imaging in medicine and surgery |
PublicationYear | 2018 |
Publisher | AME Publishing Company |
Publisher_xml | – name: AME Publishing Company |
SSID | ssj0000781710 |
Score | 2.492246 |
SecondaryResourceType | review_article |
Snippet | Lung cancer is the leading cause of cancer death in both men and women. Clinical staging plays a crucial role in predicting survivor as well as influencing... |
SourceID | pubmedcentral proquest crossref |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 709 |
SubjectTerms | Review |
Title | The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications |
URI | https://www.proquest.com/docview/2103672051 https://pubmed.ncbi.nlm.nih.gov/PMC6127520 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvZVeW3dBgLyN4jWXHlvc2RksZTcbAZXkzkixTQ-t0sf3Q_fqdI_kib2N0e3GCL3LQ9-XoSDrfOYS85UtRSCWYB2O59EIuAo8nPPDCAutww4ihY1QjrzfR6Xn4ebvazmY3TtRS28j36scfdSX_gyqcA1xRJfsPyA6Nwgn4DvjCERCG460x5s3F4rJF5Szit1-km_VCoUuMMUAWXSNdGxSQja1LZFM444LAqF5BJ9QqgevpQ6UTd-66s19bURmVGsYflVe25bIaduxNK7WjvMbQH1u_-RtYoXKUofU13k0Aih5XWIGpYJ87WZiNvhzLga3LfS3yveiS_cNn7q5i-HyIoeuMHbopHpbOci0zdwgYO1Y2NhkVfrP-rEsg8L28wkTsPjfJWdk40vW7-5sv2cn52VmWHm_TO-QugxlG4Cz0mEE85n5sclkMv8xucpuXHP3yiqlTM85UpnG2juOSPiCH3YyDfrT0eUhmunpE7q07hB6TGlhEgUUUWUQtiyiwiE5ZRAFK2hOCdiyilkUfqOUQ3RUUOEQ7Dk0fcTn0hKQnx-mnU68rxeGpIEoaTwm_wPApJlUeKBmyXAa4GBVKkchAskIEMobrYeLn8CdXS62inIs80ZIrXwRPyUG1q_QzQmPh57lizJcrHa4CKWHKjTn4YNruFzqRc3LUd2WmujT1WC3lMoPpqun8DDs_w87PsIIqm5N3wxPXNkXLX-5906OTgR3FzTFR6V1bm9ujmMEYNSfxBLahUczEPr1SlRcmI3uEZRLY8vktWn9B7o_8f0kOmn2rX4Ff28jXhoE_ATCfqtk |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+8th+lung+cancer+TNM+classification+and+clinical+staging+system%3A+review+of+the+changes+and+clinical+implications&rft.jtitle=Quantitative+imaging+in+medicine+and+surgery&rft.au=Lim%2C+Wanyin&rft.au=Ridge%2C+Carole+A&rft.au=Nicholson%2C+Andrew+G&rft.au=Mirsadraee%2C+Saeed&rft.date=2018-08-01&rft.issn=2223-4292&rft.volume=8&rft.issue=7&rft.spage=709&rft_id=info:doi/10.21037%2Fqims.2018.08.02&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2223-4292&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2223-4292&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2223-4292&client=summon |